Change of Renal Function and Bone Mineral Density in CHB Patients Switch From TDF to TAF vs. Maintaining TDF
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
In Chronic hepatitis B (CHB) patients receiving long-term sequential Neucleos(t)ides(NAs),
majority of these CHB patients experienced drug resistance and switched to Tenofovir
disoproxil fumaratate(TDF). However, some of patients on long term TDF experienced impairment
of renal function and bone mineral density. After Tenofovir alafenamide(TAF) was in clinical
practice, these group of patients got an clinical option to switch from TDF to TAF. The
investigators designed a prospective cohort study to evaluate the real life effectiveness and
safety in participants with chronic HBV infection switch from TDF to TAF vs. maintaining on
TDF.